Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 as a biomarker for the severity of COVID-19
Open Access
- 20 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in GeroScience
- Vol. 43 (1), 19-29
- https://doi.org/10.1007/s11357-020-00300-2
Abstract
Coronavirus disease 2019 (COVID-19) has a high mortality in elderly patients with pre-existing cardiovascular diseases. The cellular receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the angiotensin-converting enzyme 2 (ACE2), thereby implicating a link between cardiovascular diseases and SARS-CoV-2 susceptibility. Aortic stenosis (AS) represents a chronic inflammatory state with severe cardiovascular complications in the elderly, a prime condition for COVID-19 mortality. The circulating ACE2 levels were measured in 111 patients with severe AS and compared to patients with hypertension and healthy individuals. About 4 times higher circulating ACE2 activity was found in patients with severe AS than in hypertensives or healthy individuals (88.3 ± 61.6., n = 111, 20.6 ± 13.4, n = 540, and 16.1 ± 7.4 mU/L, n = 46, respectively). Patients with severe AS were older than patients with hypertension (80 ± 6 years vs. 60 ± 15 years, P < 0.05). Serum ACE2 activity correlated negatively with the left ventricular ejection fraction, aortic root area, TAPSE, and positively with the right ventricular systolic pressure, cardiac diameters in patients with AS. In contrast, circulating ACE2 activity was independent of the blood pressure, peak flow velocity at the aortic root, kidney function (GFR), and inflammatory state (CRP). We found no effect of RAAS inhibitory drugs on the serum ACE2 activity in this group of patients. Our results illustrate circulating ACE2 as a potential interface between chronic inflammation, cardiovascular disease, and COVID-19 susceptibility. Elderly patients with AS have markedly elevated ACE2 levels together with altered left and right ventricular functions, which may pose higher risks during COVID-19. Our clinical data do not support a role for RAAS inhibitors in regulating circulating ACE2 levels.Funding Information
- Thematic Excellence Programme of the Ministry for Innovation and Technology in Hungary (ED_18-1-2019-0028)
- European Regional Development Fund (GINOP-2.3.2-15-2016-00043, GINOP-2.3.2-15-2016-00050)
- European Social Fund (EFOP-3.6.2-16-2017-00006)
- National Research, Development and Innovation Fund of Hungary (FK 128809, K 116940, K 132623)
This publication has 29 references indexed in Scilit:
- Classification and pathophysiology of pulmonary hypertensionContinuing Cardiology Education, 2018
- Circulating ACE2 activity correlates with cardiovascular disease developmentJournal of the Renin-Angiotensin-Aldosterone System, 2016
- ACE2/Ang-(1–7)/Mas axis stimulates vascular repair-relevant functions of CD34+cellsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2015
- New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) IV: Circulating ACE2 as a Biomarker of Systolic Dysfunction in Human Hypertension and Heart FailurePLOS ONE, 2014
- New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in HumanPLOS ONE, 2014
- Aortic Stenosis in the Elderly: Disease Prevalence and Number of Candidates for Transcatheter Aortic Valve Replacement: A Meta-Analysis and Modeling StudyJournal of the American College of Cardiology, 2013
- Inflammation Is Associated with the Remodeling of Calcific Aortic Valve DiseaseInflammation, 2012
- Hyaluronan Esters Drive Smad Gene Expression and Signaling Enhancing Cardiogenesis in Mouse Embryonic and Human Mesenchymal Stem CellsPLOS ONE, 2010
- Cardiac Overexpression of Angiotensin Converting Enzyme 2 Protects the Heart From Ischemia-Induced PathophysiologyHypertension, 2008
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005